Medtronic (NYSE:MDT) Shares Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Medtronic Stock Performance

MDT stock traded down $2.18 during trading on Friday, reaching $96.82. 9,034,766 shares of the company’s stock were exchanged, compared to its average volume of 5,557,880. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The firm has a market cap of $124.12 billion, a PE ratio of 26.10, a P/E/G ratio of 2.55 and a beta of 0.71. The company’s fifty day moving average price is $98.99 and its 200-day moving average price is $94.88. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is presently 76.55%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MDT shares. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Barclays boosted their target price on Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Sanford C. Bernstein lifted their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $110.28.

Hedge Funds Weigh In On Medtronic

A number of hedge funds and other institutional investors have recently modified their holdings of MDT. Corundum Trust Company INC purchased a new stake in Medtronic in the 3rd quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic in the fourth quarter worth $27,000. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic during the fourth quarter worth $29,000. GoalVest Advisory LLC acquired a new stake in Medtronic during the fourth quarter valued at $29,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Medtronic during the third quarter valued at $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).